KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBT (2016 - 2025)

Historic EBT for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $25.7 million.

  • Travere Therapeutics' EBT rose 14689.26% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 7460.61%. This contributed to the annual value of -$320.5 million for FY2024, which is 1478.29% up from last year.
  • As of Q3 2025, Travere Therapeutics' EBT stood at $25.7 million, which was up 14689.26% from -$12.7 million recorded in Q2 2025.
  • Travere Therapeutics' EBT's 5-year high stood at $25.7 million during Q3 2025, with a 5-year trough of -$135.8 million in Q1 2024.
  • Its 5-year average for EBT is -$67.0 million, with a median of -$80.0 million in 2022.
  • In the last 5 years, Travere Therapeutics' EBT crashed by 19477.1% in 2021 and then soared by 14689.26% in 2025.
  • Over the past 5 years, Travere Therapeutics' EBT (Quarter) stood at -$88.8 million in 2021, then grew by 3.6% to -$85.6 million in 2022, then dropped by 3.45% to -$88.5 million in 2023, then surged by 31.84% to -$60.3 million in 2024, then surged by 142.62% to $25.7 million in 2025.
  • Its EBT was $25.7 million in Q3 2025, compared to -$12.7 million in Q2 2025 and -$41.2 million in Q1 2025.